This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Leyssen, P. Articles by Neyts, J. Search for Related Content PubMed PubMed Citation Articles by Leyssen, P. Articles by Neyts, J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2003, p. 777-782, Vol. 47, No. 2
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.2.777-782.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Interferons, Interferon Inducers, and Interferon-Ribavirin in Treatment of Flavivirus-Induced Encephalitis in Mice

Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium,¹ Bernhard Nocht Institute of Tropical Medicine, Hamburg, Germany²

Received 19 June 2002/ Returned for modification 12 September 2002/ Accepted 14 November 2002

We evaluated the prophylactic and therapeutic efficacy of interferon -2b, pegylated interferon -2b, poly(I · C), and Ampligen against Modoc virus encephalitis in an animal model for flavivirus infections. All compounds significantly delayed virus-induced morbidity (paralysis) and mortality (due to progressive encephalitis). Viral load (as measured on day 7 postinfection) was significantly reduced by 80 to 100% in the serum, brain, and spleen in mice that had been treated with either interferon -2b, pegylated interferon -2b, poly(I · C), or Ampligen. We also studied whether a combination of interferon -2b and ribavirin (presently the standard therapy for the treatment of infections with hepatitis C virus) would be more effective than treatment with interferon alone. However, ribavirin did not enhance the inhibitory effect of interferon therapy in this animal model for flavivirus infections.

This article has been cited by other articles:

• Bourne, N., Scholle, F., Silva, M. C., Rossi, S. L., Dewsbury, N., Judy, B., De Aguiar, J. B., Leon, M. A., Estes, D. M., Fayzulin, R., Mason, P. W. (2007). Early Production of Type I Interferon during West Nile Virus Infection: Role for Lymphoid Tissues in IRF3-Independent Interferon Production. J. Virol. 81: 9100-9108 [Abstract] [Full Text]  
• Gowen, B. B., Wong, M.-H., Jung, K.-H., Sanders, A. B., Mitchell, W. M., Alexopoulou, L., Flavell, R. A., Sidwell, R. W. (2007). TLR3 Is Essential for the Induction of Protective Immunity against Punta Toro Virus Infection by the Double-Stranded RNA (dsRNA), Poly(I:C12U), but not Poly(I:C): Differential Recognition of Synthetic dsRNA Molecules. J. Immunol. 178: 5200-5208 [Abstract] [Full Text]  
• Georges-Courbot, M. C., Contamin, H., Faure, C., Loth, P., Baize, S., Leyssen, P., Neyts, J., Deubel, V. (2006). Poly(I)-Poly(C12U) but Not Ribavirin Prevents Death in a Hamster Model of Nipah Virus Infection.. Antimicrob. Agents Chemother. 50: 1768-1772 [Abstract] [Full Text]  
• Samuel, M. A., Diamond, M. S. (2005). Alpha/Beta Interferon Protects against Lethal West Nile Virus Infection by Restricting Cellular Tropism and Enhancing Neuronal Survival. J. Virol. 79: 13350-13361 [Abstract] [Full Text]  
• Asper, M., Sternsdorf, T., Hass, M., Drosten, C., Rhode, A., Schmitz, H., Gunther, S. (2004). Inhibition of Different Lassa Virus Strains by Alpha and Gamma Interferons and Comparison with a Less Pathogenic Arenavirus. J. Virol. 78: 3162-3169 [Abstract] [Full Text]  
• Padalko, E., Nuyens, D., De Palma, A., Verbeken, E., Aerts, J. L., De Clercq, E., Carmeliet, P., Neyts, J. (2004). The Interferon Inducer Ampligen [Poly(I)-Poly(C12U)] Markedly Protects Mice against Coxsackie B3 Virus-Induced Myocarditis. Antimicrob. Agents Chemother. 48: 267-274 [Abstract] [Full Text]